Business Context and Reporting Period
Company: Urogen Pharma Ltd. (URGN)
Filing Type: Form 8-K (Current Report)
Date of Report: June 2, 2026
Event: Announcement of a settlement and license agreement with Teva Pharmaceuticals, Inc. regarding the product Jelmyto (mitomycin) for pyelocalyceal solution.
Key Financial Metrics
This filing is a current report regarding a legal settlement and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Agreement Terms
- Resolution of Litigation: The agreement resolves patent litigation initiated by Teva's submission of an Abbreviated New Drug Application (ANDA) for a generic version of Jelmyto.
- Licensing Terms: Urogen Pharma will grant Teva a non-exclusive license to sell the generic version of Jelmyto in the United States.
- Effective Date: The license is effective beginning September 15, 2030, contingent upon FDA approval and the absence of certain limited customary circumstances.
- Legal Action: All ongoing patent litigation between the parties in the U.S. District Court for the District of Delaware will be terminated.
Outlook, Risks, and Contingencies
- Regulatory Review: The Agreement is subject to review by the U.S. Federal Trade Commission (FTC) and the U.S. Department of Justice (DOJ).
- Approval Contingency: Teva's ability to sell the generic product is contingent on FDA approval.
- Future Cash Flow Impact: While specific financial terms (e.g., upfront payments or royalties) are not detailed in this text, the agreement establishes a defined timeline for generic market entry in 2030.
Investor Verification Checklist
- Verify the specific financial consideration (upfront payments, milestones, or royalties) associated with the settlement, as these details are not included in this 8-K summary.
- Monitor the status of the FTC and DOJ regulatory review to confirm the agreement's final approval.
- Confirm the FDA approval status of Teva's generic Jelmyto application to assess the likelihood of the September 15, 2030 launch date.
- Review the full text of the settlement agreement for any "limited circumstances" that could alter the 2030 launch date.